Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

errol de souza

  • Home
  •  
  • errol de souza



  • Most Read
  • Latest Comments
  • Uh oh…People: A new approach to treating Social Anxiety Disorder
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Uh oh…People: A new approach to treating Social Anxiety Disorder
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Uh oh…People: A new approach to treating Social Anxiety Disorder
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Uh oh…People: A new approach to treating Social Anxiety Disorder
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Uh oh…People: A new approach to treating Social Anxiety Disorder
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Mesoblast receives FDA support for accelerated approval pathway for heart failure treatment
    Mesoblast receives FDA support for accelerated approval pathway for heart failure treatment
    • News

  • As cash dwindles, Advanced Health Intelligence lists collabs and partnerships to turn things around
    As cash dwindles, Advanced Health Intelligence lists collabs and partnerships to turn things around
    • News

  • FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    • News

  • AFT’s pain relief medication Maxigesic gets FDA approval, but the IV version still under scrutiny
    AFT’s pain relief medication Maxigesic gets FDA approval, but the IV version still under scrutiny
    • News

  • Understanding the importance of clinical trials when investing in medical research driven biotech
    Understanding the importance of clinical trials when investing in medical research driven biotech
    • Explainers

  • Uh oh…People: A new approach to treating Social Anxiety Disorder
    • News

    Uh oh…People: A new approach to treating Social Anxiety Disorder

    If the festive season has left you feeling depleted and ready for a solid few nights in, cemented to the couch, you’re not alone. Social interactions can be draining at the best of times for my fellow introverts, but it’s even tougher for those with Social Anxiety Disorder.  According to the Diagnostic and Statistical Manual

    Read More
    Public
  • Bionomics granted Fast Track approval from FDA to study PTSD drug
    • News

    Bionomics granted Fast Track approval from FDA to study PTSD drug

    Once upon a time, stress ensured our survival. When faced with a dangerous situation our body responds instantly- heart rate increases, blood pressure climbs and muscles tighten as the body prepares to deal with the bear/ exam you’ve been presented with.  In the modern world we are faced with a disproportionately higher amount of exams

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.